After a long, strange trip, this CEO is close to taking a psilocybin pill to market

In 2022, Kabir Nath had a cushy administrator job at a pharmaceutical firm that developed anti-psychotic medication.

Then he got a call from a scrappy upstart alongside a patent on a synthetic type of psilocybin — the energetic component in magic mushrooms. It hoped to use the compound to assistance those alongside treatment-resistant depression.

They wanted him to associate as CEO. Nath, whose begetter died by suicide, bit on their second pitch.

"A figure of group have stated to me in the final brace of years: 'You do acknowledge what a hazard that was,'" Nath told Business Insider concerning eventually jumping container for what was, and motionless is, a medication business without FDA approval for its product.

"I was likely the archetypal really elder administrator from traditional pharma to create the move to psychedelics," he added. "But, you know, it was the correct item to do."

Nath's individual hazard is now magnified as Compass Pathways finishes filing its final forms onward of what could be FDA endorsement as shortly as next year, and afterward a community rollout of its psilocybin pill, called COMP360.

Compass has lately added 150 new hires to its payroll, expanded its promotion division, and moved into new agency area in Jersey City in the anticipation it all plant out. "The business is expanding rapidly," Nath said.

Though a subsidiary of Johnson and Johnson attained FDA endorsement alongside a type of ketamine for decline patients in 2019, it is by no method guaranteed that Compass, leveraging a additional traditional psychedelic, volition get the identical approval.

Should the FDA refuse Compass' bid, investors would hurry to dump their shares, apt sending the business into bankruptcy. The Jersey City office, which fair received a new lime green coat job, would be untenable.

If you ask Nath, it would additionally be bad news for 4 myriad patients alongside depression in the US, for whom additional traditional antidepressants akin SSRIs don't work.

"These are group who have been suffering from depression, and nothing's really working," he said.

Like another medication companies — particularly those alongside a sole merchandise — Compass' inventory has "been on fairly the adventure," Nath said, as the business progressed through assorted individual trials.

When markets closed on Friday, the portion cost hovered about $11, up $5 from final year. In 2020, whenever the business went public, shares went for $17.

From Haight Ashbury to Wall Street

Psilocybin's journey to the forefront of medicinal investigation didn't commencement alongside Compass, and it hasn't exactly gone in a direct line.

Few did additional to publicize the medication than Timothy Leary, the Harvard prof turned acidic dropout. In a address at Harvard's Cambridge evidence in 1962, he told students that taking psilocybin allows group to cognition an "internal rebirth," according to the Harvard Crimson.

In time, Leary would be fired from Harvard as he, alongside alongside a measurable part of the US population, began to test additional heavily alongside psychedelic drugs. Come 1966, the Grateful Dead were spiking their Kool-Aid alongside acid, and a conclusive subculture of long-haired, psychedelic-taking hippies had emerged.

Meanwhile, researchers were experimenting too. Studies involving LSD and psilocybin flourished during the 1960s before hitting a masonry block partition in 1970, whenever psilocybin was classified as a Schedule I substance, rendering possession illegal, equal for investigation purposes.

Work on the medication languished for years, until 2000, whenever the FDA gave scientists at Johns Hopkins University approval to behavior investigation on psilocybin.

And additional recently, psychedelics have rotate into trendy alongside the tech crowd.

From Burning Man to luxury retreats, experimenting alongside psychedelics is now average among tech founders and executives akin Elon Musk and Sam Altman, who credit the drugs alongside quieting their nerves, boosting productivity, and allowing them to improved harness their creativity.

Research, too, has flourished.

"There was really a biotech surge from 2018 through to concerning 2022," Nath said. "In that boom, exactly hundreds of psychedelic companies went public."

In 2018, Compass' proprietary psilocybin formulation received breakthrough therapy heading from the FDA. A few years later, it started evaluation the medication on people.

Nath was an administrator in 2018 at Japanese pharmaceutical elephantine Otsuka, anywhere he stated he assembled a squad to examine whether psychedelics could rotate into viable medicines following study Michael Pollan's publish "How to Change Your Mind," which explores the former and therapeutic possible of psychedelics.

COMP360

Compass isn't marketing an cognition akin to a religious awakening at Burning Man, though.

The drug-taking procedure for a tolerant enrolled in one of Compass' trials is a bit different. First, a tolerant has to have treatment-resistant depression, which is clinically defined as decline that two or additional norm narcotics have unsuccessful to treat.

Then, a clinician explains the particulars of the procedure that is concerning to unfold. After that, they're stated the psilocybin in pill form.

"It's a quiescent area alongside a couch," Nath said. "They're offered a blindfold, which most patients do really wear."

As the tolerant starts to trip, a playlist of music, including traditional and new age, plays quietly in the background. The clinician, who Nath stated could be a nurse, doctor, or therapist, sits silently in the area if the tolerant wants to talk, and for safety reasons.

Most of the time, though, there isn't any talking.

"This is not psychotherapy," Nath said. "We are not directing the patient's experience."

Six hours later, following several crying, laughing, and everything in between, the tolerant goes home.

In Compass's most latest trial, results for which were published in September, fair under fractional of participants who took the medication informed at smallest a 50% decrease in depressive symptoms inside six weeks of treatment.

Next steps

After a decade of slogging through tests, archetypal on animals and afterward on humans, Compass has completed all the necessary prerequisites and is busily operating to get its final document in order.

In a declaration provided to Business Insider, an FDA spokesman was noncommittal, though.

"The FDA evaluates experimental medications, including psychedelic narcotics akin psilocybin, through a rigorous, evidence-based procedure designed to justify that any approved care is harmless and productive for the indicated use," the spokesman said.

Compass isn't the lone psychedelic medication business wading through the lengthy procedure of trialing a drug.

AtaiBeckley, another psychedelic medication business selling on the Nasdaq whose merchandise is not yet approved by the FDA, is evolving a type of DMT administered via nasal spray. It received breakthrough position in 2025, years rearward Compass.

For Compass, though, it could visage the music as shortly as the archetypal fractional of next year, whenever it expects the FDA to render its decision. The business is already getting ready.

In supplement to adding 150 new hires, Nath stated the business is preparing its revenue power to go online and is in common communication alongside doctors and healthcare providers concerning functioning in clinics anywhere therapists can oversee the medication to patients.

"This has the possible to be radically different, and again, the rapidity is item that they're extremely enthusiastic about, and the durability," Nath said, referring to psychiatrists.